Oncolytics Biotech Inc T.ONC

AWARE-1 data analyzed showing Pelareorep priming of TME

[Noteable]

To understand the complex tumor microenvironment (TME) and immune responses in patients before and after treatment, we used imaging mass cytometry (IMC) to perform single cell, highly multiplexed, analysis of their tissue samples.

In accordance with the prior AWARE-1 results, IMC demonstrated an enhanced immune state of the tumors after treatment.

Results confirm previous data from the window of opportunity AWARE-1 study demonstrating synergy between pelareorep in combination with atezolizumab, and a favorable immunologic response in tumors from early breast cancer (eBC) patients.

https://jitc.bmj.com/content/11/Suppl_1/662

[Noteable]

November 2023 - Volume 11 - Suppl 1 SITC 38th Annual Meeting (SITC 2023) Abstracts https://jitc.bmj.com/content/11/Suppl_1 https://jitc.bmj.com/search/Pelareorep%252B%20jcode%3Ajitc

[Noteable]

AWARE-1's patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) the PD-L1 inhibitor atezolizumab (Tecentriq®) prior to surgery. Pelareorep treatment in cohort 1 upregulated tumor PD-L1 expression, induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ T cells, and increased the CelTIL score, a measure of tumor